Aptar Pharma hosts “The Nasal drug Delivery Journey: From Systemic to Nose-to-Brain" scientific webinar
Webinar will focus on the nasal drug delivery route in the treatment of central nervous system diseases.
Aptar Pharma will host an online scientific event focused on the nasal drug delivery route in the treatment of central nervous system (CNS) diseases. The panel will be composed of our experts, Pierre Carlotti and Gerallt Williams (Aptar Pharma), and Julie Suman (Next Breath). Participants may join this webinar on 8 September (4 PM – Paris time/10 AM New York time).
The webinar will be presented live and will include interactive exchanges with registered participants.
The Aptar Pharma webinar will feature discussions on the following topics:
• Unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases
• Drug transport into the CNS via the nasal route
• Nasal drug delivery devices that target CNS-related diseases
• New opportunities in areas such as nose-to-brain drug delivery.
By 2030, one billion people worldwide will be over the age of 65 compared to 600 million today. Healthcare must adjust to these changing demographics. In addition, the world is facing multiple unmet medical needs.
Several changes - new therapeutic options, shorter hospital stays, increased outpatient care and more self-administration of drugs, to name a few – are imperative within a short time frame. The pharmaceutical and biotech industries are striving to provide affordable solutions to these challenges.
This environment provides a wide range of opportunities for the CNS drug market ($145 billion in 2015) in the future treatment of patients. Covering areas such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, migraine, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety and bipolar disorders, new CNS drug delivery options will benefit patients and enhance overall healthcare.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance